Atazanavir And Cobicistat
Tablet · trading as Evotaz
To Be Discontinued Active (discontinuing) — Day 192
High impact — Sole-source drug with no supply currently available from this manufacturer.
FDA shortage record
- Substance
- Atazanavir And Cobicistat
- Brand name
- Evotaz
- Manufacturers / suppliers
-
- E.R. Squibb & Sons, L.L.C.
- Bristol Myers Squibb Co.
- Dosage form
- Tablet
- Presentation
- Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11)
- Route(s)
- ORAL
- Therapeutic category
- Antiviral
- Package NDC
0003-3641-11- Initially posted
- 11/03/2025
- Days on shortage list
- 192
- Discontinued
- 11/03/2025
- Current FDA status
- To Be Discontinued
- Shortage entries (current dataset)
- 1 record for Atazanavir And Cobicistat
Reason and context
The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-332-2056.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
83db29d7-5d85-49d6-8cb6-740473365cf8). - FDA UNII identifier:
4MT4VIE29P. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.